Praxis Precision Medicines Slides as Investors Weigh Earlier Trial Miss and Upcoming FDA Decisions

2026-09-23

Investivoq PriceTracker

Praxis Precision Medicines (PRAX) is down 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a mix of biotech volatility and profit-taking rather than a fresh negative announcement. The stock is still trading against the backdrop of a June setback for vormatrigine, while investors also appear to be reassessing risk around Praxis’ late-2026 and early-2027 FDA catalysts. ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-vormatrigine-program-update))

Details:

Praxis’ June 1 update said the POWER1 study for vormatrigine in focal onset seizures did not meet its primary success measure, even though a secondary responder endpoint was met and the drug was generally well tolerated. ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-vormatrigine-program-update))

In its August corporate update, Praxis said it is using lessons from POWER1 to restart POWER2 and begin POWER3 in the fourth quarter of 2026, showing the epilepsy program remains in transition rather than fully de-risked. ([investors.praxismedicines.com](https://investors.praxismedicines.com/node/11596/pdf))

The company’s relutrigine NDA review was extended in June, moving the FDA target action date to December 27, 2026 after additional sensitivity analyses were submitted as a major amendment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm?utm_source=openai))

Praxis has still described both relutrigine and ulixacaltamide reviews as progressing without major safety or efficacy concerns so far, which suggests today’s drop could be because traders are reducing exposure ahead of binary regulatory events rather than reacting to a new operational problem. ([investors.praxismedicines.com](https://investors.praxismedicines.com/node/11596/pdf))

Sources:

Praxis Precision Medicines, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PRAX Insider Trading Activity

$PRAX insiders have traded $PRAX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:

JILL DESIMONE has made 0 purchases and 12 sales selling 11,600 shares for an estimated $3,611,334.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

EARLY ACCESS

Receive PRAX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$PRAX Hedge Fund Activity

We have seen 184 institutional investors add shares of $PRAX stock to their portfolio, and 149 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ORBIS ALLAN GRAY LTD removed 942,692 shares (-38.1%) from their portfolio in Q2 2026, for an estimated $315,603,854
POINT72 ASSET MANAGEMENT, L.P. removed 492,346 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $158,628,957
INVESCO LTD. added 476,151 shares (+775.5%) to their portfolio in Q2 2026, for an estimated $159,410,593
ASSENAGON ASSET MANAGEMENT S.A. removed 408,787 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $131,707,083
RA CAPITAL MANAGEMENT, L.P. removed 373,787 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $125,140,149
NORGES BANK added 342,615 shares (+7869.0%) to their portfolio in Q2 2026, for an estimated $114,704,075
PRICE T ROWE ASSOCIATES INC /MD/ added 312,147 shares (+49.5%) to their portfolio in Q2 2026, for an estimated $104,503,694

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$PRAX Congressional Stock Trading

Members of Congress have traded $PRAX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PRAX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 07/30.

To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

$PRAX Analyst Ratings

Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/02/2026

To track analyst ratings and price targets for $PRAX, check out Investivoq's $PRAX forecast page.

$PRAX Price Targets

Multiple analysts have issued price targets for $PRAX recently. We have seen 9 analysts offer price targets for $PRAX in the last 6 months, with a median target of $575.0.

Here are some recent targets:

Ami Fadia from Needham set a target price of $575.0 on 06/29/2026
Leonid Timashev from RBC Capital set a target price of $449.0 on 06/18/2026
Laura Chico from Wedbush set a target price of $162.0 on 06/02/2026
Jay Olson from Oppenheimer set a target price of $650.0 on 06/02/2026
Joel Beatty from Baird set a target price of $400.0 on 06/02/2026
Danielle Brill from Truist Securities set a target price of $616.0 on 06/02/2026
David Hoang from Deutsche Bank set a target price of $374.0 on 06/02/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.